M. C. St. Paul - Infectious Diseases

Author Information

Mical Paul is affiliated with the Infectious Diseases Institute at Rambam Health Care Campus and the Rappaport Faculty of Medicine and Research Institute, Technion-Israel Institute of Technology in Haifa, Israel. This affiliation highlights their involvement in both clinical and academic settings, contributing to the advancement of infectious disease research and treatment.

Research Contributions

Mical Paul has made significant contributions to the field of infectious diseases, with a particular focus on antimicrobial resistance and the treatment of drug-resistant bacterial infections. Their recent publications from 2022 include studies on cefiderocol for treating metallo-beta-lactamase-producing pathogens, the clinical pipeline for drug-resistant bacterial infections, and the epidemiology of carbapenemase-producing Enterobacterales. They have also explored the use of whole genome sequencing for understanding the dissemination of carbapenem-resistant Acinetobacter baumannii and analyzed the efficacy of different durations of antibiotic treatments for uncomplicated Gram-negative bloodstream infections.

Aliases

The author has been identified with several aliases including "M Paul," "M. C. St. Paul," and "M. Paul." However, the full name "Mical Paul" is used when possible to provide clarity and ensure accurate attribution of their work.

Publication and Citation Metrics

Metric	Value
Total Citations	23,406
H-Index	79
Total Papers	479

Publications:

Cefiderocol for the Treatment of Infections Due To Metallo-Beta-Lactamase-Producing Pathogens in the CREDIBLE-CR And APEKS-NP Phase 3 Randomized Studies.

DOI: 10.1093/cid/ciac078

Year: 2022

Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed

DOI: 10.1128/aac.01991-21

Year: 2022

Reply to Kaye and Belley, “Third-Generation Cephalosporin-Resistant Enterobacterales Are Critical Priority Pathogens, Too!”

DOI: 10.1128/aac.00223-22

Year: 2022

Large-scale WGS of carbapenem-resistant Acinetobacter baumannii isolates reveals patterns of dissemination of ST clades associated with antibiotic resistance.

DOI: 10.1093/jac/dkac010

Year: 2022

A Desirability of Outcome Ranking (DOOR) Analysis of a Randomized Clinical Trial Comparing Seven Versus Fourteen Days of Antibiotics for Uncomplicated Gram-Negative Bloodstream Infection

DOI: 10.1093/ofid/ofac140

Year: 2022

The Changing Epidemiology of Carbapenemase-Producing Enterobacterales

DOI: 10.5041/RMMJ.10461

Year: 2022

Piperacillin–tazobactam versus meropenem for treatment of bloodstream infections caused by third-generation cephalosporin-resistant Enterobacteriaceae: a study protocol for a non-inferiority open-label randomised controlled trial (PeterPen)

DOI: 10.1136/bmjopen-2020-040210

Year: 2021

Q fever vertebral osteomyelitis among adults: a case series and literature review

DOI: 10.1080/23744235.2020.1871508

Year: 2021

Reporting of systematic reviews and meta-analysis of observational studies

DOI: 10.1016/j.cmi.2020.11.006

Year: 2021

European Society of clinical microbiology and infectious diseases (ESCMID) guidelines for the treatment of infections caused by Multidrug-resistant Gram-negative bacilli (endorsed by ESICM –European Society of intensive care Medicine)

DOI: 10.1016/j.cmi.2021.11.025

Year: 2021

What is HIV?

How can drug interactions impact treatment outcomes?

How Do Pathogens Exploit Host Metabolic Pathways?

What Is the Relationship Between Climate Change and Food Security?

What are Antiviral Drugs?

How Do CRISPR-Cas Systems Work?

What Could Be Causing Weight Loss?

What Role Does Sanitization Play in Infection Control?

What is a PCR Test?

How Does the Inflammatory Response Work?

Partnered Content Networks

Relevant Topics